Senior Scientist I/II, Antibody Engineering (Phage Display)

Sorry, this job was removed at 04:57 p.m. (CST) on Friday, Oct 04, 2024
Be an Early Applicant
South San Francisco, CA
145K-185K Annually
3-5 Years Experience
Biotech
The Role

Lycia Therapeutics, Inc. is a biotechnology company leveraging its lysosomal targeting chimera (LYTAC) platform from Founder and Chemistry Nobel Laureate 2022, Carolyn Bertozzi, to discover and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins. Lycia’s next generation degraders harness the cell’s endogenous lysosomal trafficking and degradation machinery with the potential to degrade targets previously considered to be intractable, across a spectrum of indications. After raising $105 million in capital in 2021, Lycia is advancing an internal pipeline of novel degraders and has entered a strategic collaboration with Eli Lilly to address key unmet medical needs. In May 2024, Lycia Therapeutics completed a $106.6 million series C financing to advance its pipeline of LYTAC extracellular protein degraders to the clinic. Lycia is headquartered in South San Francisco. 


Visit https://lyciatx.com/ for more information.


The Role:

Lycia Therapeutics is seeking a team-oriented and talented individual to join our Antibody Engineering team in the Biologics group as a Senior Scientist I/II. In this role, you will leverage your expertise in antibody phage display technologies, biochemical assays, and high throughput bacterial protein expression to discover novel antibodies or engineer existing antibodies with desired properties. 


The candidate will work closely with members of the Biologics and Biology groups as part of an innovative research organization to advance LYTACs to the clinic.


Key Responsibilities:

  • Utilize phage display methodologies to discover novel antibodies or engineer existing antibodies to improve their functional activities.
  • Use state-of-the-art phage display methods and high throughput ELISA-based and FACS-based screening. 
  • Use BLI (Gator or Octet) or SPR (Biacore) based platforms to perform kinetic characterizations of antibody fragments or monoclonal antibodies.
  • Perform high-throughput sequence analysis of potential candidates using sequence analysis software (e.g. Geneious Prime and AbYsis)
  • Regularly communicate results to company supervisors, present updates during internal or joint team meetings with other companies.
  • Multi-task, plan, execute, and deliver on projects which may be run in parallel.
  • Identify and promptly troubleshoot technical issues.
  • Maintain detailed lab records and perform electronic data management.
  • Participate in reagent and lab supplies procurement and perform and/or oversee routine maintenance on instruments and equipment.

Requirements:

  • Ph.D. with 4+ years of experience in molecular biology, biochemistry, chemical engineering or related field is required
  • Phage display experience is required
  • Extensive experience in ELISA based screening is required
  • Deep knowledge of molecular biology techniques and PCR is highly desired.
  • Knowledge of DNA sequence analysis software is required
  • Knowledge of FACS screening and analysis is desired.
  • Experience with SPR/BLI is desired but not required.
  • Excellent attention to detail, record keeping, and communication skills.
  • Strong ability to work independently and manage work with minimal supervision.

We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status

The Company
HQ: South San Francisco, California
39 Employees
On-site Workplace
Year Founded: 2020

What We Do

Lycia is a Series B biotech company building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes in circulation and depleting antibodies to specific antigens of interest. The platform can potentially deliver next-generation therapeutics to address a range of difficult-to-treat diseases, including cancer and autoimmune diseases.

Jobs at Similar Companies

Pfizer Logo Pfizer

Crew Scheduler

Artificial Intelligence • Healthtech • Machine Learning • Natural Language Processing • Biotech • Pharmaceutical
Hybrid
West Trenton, NJ, USA
121990 Employees
65K-108K Annually

Takeda Logo Takeda

R&D Head Digital, Data, & Technology (DD&T)

Healthtech • Software • Analytics • Biotech • Pharmaceutical • Manufacturing
Hybrid
Boston, MA, USA
50000 Employees

SOPHiA GENETICS Logo SOPHiA GENETICS

BioPharma Business Development Director

Artificial Intelligence • Big Data • Healthtech • Software • Biotech
3 Locations
450 Employees

Similar Companies Hiring

SOPHiA GENETICS Thumbnail
Software • Healthtech • Biotech • Big Data • Artificial Intelligence
Boston, MA
450 Employees
Pfizer Thumbnail
Pharmaceutical • Natural Language Processing • Machine Learning • Healthtech • Biotech • Artificial Intelligence
New York, NY
121990 Employees
Takeda Thumbnail
Software • Pharmaceutical • Manufacturing • Healthtech • Biotech • Analytics
Cambridge, MA
50000 Employees

Sign up now Access later

Create Free Account

Please log in or sign up to report this job.

Create Free Account